Market Overview

Bernstein Weighs In On Vertex Move

Share:
Related VRTX
Credit Suisse Adjusts Its Top Picks List In A Record-Breaking Market
Earnings Scheduled For October 25, 2017

As shares of Vertex Pharmaceuticals (NASDAQ: VRTX) have rallied over 40 percent following a press release concerning phase 3 studies of its Lumacaftor Ivacaftor combination regime, Bernstein analyst Geoffrey Porges issued a note with his take on the stock

Despite Tuesday's move, Porges maintained his Market Perform rating and $65 price target.

Porges noted the data are "clearly better than expected," but believes the immediate potential of the combination is substantially priced in. Moreover, he thinks short-covering will initially exaggerate the move.

Looking forward, Porges expects the regimen to receive FDA approval.

For a more detailed look into the press release, click here.

Latest Ratings for VRTX

DateFirmActionFromTo
Sep 2017DA DavidsonInitiates Coverage OnBuy
Sep 2017RBC CapitalInitiates Coverage OnOutperform
Jul 2017CitigroupMaintainsBuy

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings

Posted-In: Bernstein Geoffrey PorgesAnalyst Color News Price Target Reiteration Analyst Ratings

 

Related Articles (VRTX)

View Comments and Join the Discussion!

Partner Center